Stockreport

Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients [Yahoo! Finance]

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF topline results from its Phase 3 SCOUT-HCM clinical trial. This study evaluated Camzyos (mavacamten), which is a cardiac myosin inhibitor/CMI, in adolescent patients age [Read more]